The phone call comes every month like clockwork. Your pharmacy doesn’t have your medication. Again. They might get it next week, or maybe the week after. No promises. You make six more calls, driving across town, only to hear the same apologetic response at each stop.
If this sounds familiar, you’re living through one of the most frustrating healthcare disruptions of the past few years. But there’s a cautious reason for hope.
In mid-September 2025, the Drug Enforcement Administration took action. They raised the legal production limits for lisdexamfetamine (the generic name for Vyvanse) and the chemical ingredients needed to manufacture it. The official order went into effect immediately, citing ongoing shortages and manufacturers struggling to source active ingredients.
Two weeks later, on October 2, the DEA followed up with additional quota increases for d-amphetamine and methylphenidate, the medications in Adderall and Ritalin products. These moves matter because they set the annual ceiling for how much manufacturers can legally produce.
But here’s what nobody wants to hear: higher quotas don’t translate to instant relief. When you check the American Society of Health-System Pharmacists shortage database, many strengths and formulations still show limited availability. The fix is real, but it’s going to arrive unevenly.
Why the Wait Feels So Long
Think of production quotas like opening a dam gate wider. The water can flow faster now, but it still has to travel downstream through the entire system.
Pharmaceutical manufacturing isn’t like flipping a switch. Companies need to secure raw materials, which might be sourced internationally. They run production batches under strict quality control standards, testing each lot for potency and purity. Then finished medications move through distribution networks, wholesalers, and finally to your local pharmacy.
There’s another wrinkle. Some wholesalers and pharmacies use monitoring systems to flag unusual ordering patterns as part of their compliance programs. The DEA doesn’t mandate these limits, but companies create their own thresholds to avoid regulatory scrutiny. This well-intentioned caution can create pockets of scarcity even when national supply improves.
What this means in practical terms: your experience depends heavily on which specific medication you take, what dose, and where you live. One strength might return to normal availability while another stays backordered. Generic versions might show up before brand names, or vice versa. The national picture improving doesn’t guarantee your local pharmacy will have your specific prescription ready next week.
Seven Real Options When Your Medication Is Out of Stock
You don’t have to wait helplessly. Here are concrete strategies that work within the system as it exists right now.
Move your prescription to a pharmacy that has stock. This used to require getting a brand new prescription from your doctor for Schedule II medications like stimulants. Not anymore. New federal rules allow pharmacies to electronically transfer unfilled prescriptions to another location one time. Ask your pharmacist to check availability at other stores and transfer your e-prescription directly. You avoid the hassle of contacting your doctor and waiting for a new script.
Ask if they have a different strength that could work. Your pharmacy might be out of 30 mg capsules but have plenty of 20 mg in stock. Or they might have the chewable version when regular capsules are scarce. Your prescriber can adjust the prescription if it makes clinical sense. One important note: medication labels specifically warn against splitting Vyvanse capsules into multiple doses. The entire capsule should be taken at once, though you can open it and mix the contents with liquid if swallowing pills is difficult.
Consider switching formulations temporarily. Some people can move between immediate-release and extended-release versions, or try a different generic manufacturer. This requires careful conversation with your prescriber because dose conversions need clinical judgment, not guesswork. What works for one person might not work for another, and the transition needs professional guidance.
Use a partial fill to bridge the gap. Here’s something many people don’t know: federal regulations allow pharmacies to dispense part of a Schedule II prescription when they can’t fill the full amount right away. You get what they have now, and they fill the rest when it comes in. State rules vary on the specifics and time limits, so ask your pharmacist what’s possible in your area.
Talk to your doctor about non-stimulant alternatives. Medications like atomoxetine, viloxazine, guanfacine, and clonidine work through different mechanisms than stimulants. They typically take longer to show effects, but clinical guidelines recognize them as evidence-based options for ADHD management. They’re not right for everyone, and they won’t feel the same as your stimulant medication. But for some people facing prolonged access issues, they offer a way to maintain treatment continuity.
Tap into telehealth access while it’s available. The pandemic-era rules that made it easier to get controlled substance prescriptions via telehealth haven’t expired. The temporary flexibilities remain in place through December 31, 2025, giving you legal access to care even if your usual prescriber isn’t available or you’ve recently moved. These rules will eventually become permanent or change, but for now, telehealth remains a legitimate option.
Protect yourself from dangerous alternatives. Desperation creates vulnerability. The CDC issued a health alert warning that medication shortages increase the risk of people turning to unlicensed sources. Counterfeit pills can contain anything, including lethal doses of fentanyl. No shortage is worth risking your life. If you’re struggling with access, talk honestly with your healthcare team about safety planning and consider having naloxone available as a precaution.
What People Are Really Asking
So the quotas went up. What does that actually mean for me?
The September 19 increase applied to lisdexamfetamine and to d-amphetamine used as a chemical building block in manufacturing. The October 2 boost covered d-amphetamine and methylphenidate for direct sale. Both changes remove a regulatory ceiling that was constraining production. Manufacturers can now legally make more, but they still need time to scale up, produce, test, and distribute.
Can I still get my stimulant prescription through telehealth?
Yes. Federal telemedicine prescribing rules for controlled substances continue through at least the end of 2025 while permanent regulations are developed. You still need to follow your state’s requirements, which might include additional steps or restrictions.
What if my pharmacy says they can’t transfer Schedule II prescriptions?
They might not know about the rule change. The federal regulation allowing one-time electronic transfers of unfilled Schedule II prescriptions took effect in 2023. It only works for electronic prescriptions, not paper ones, and the transfer must happen directly between pharmacies. If your pharmacist isn’t familiar with the rule, you can mention it’s in the Federal Register from July 2023.
Are generic and brand versions really the same thing?
The FDA requires that approved generics be therapeutically equivalent to brand-name medications. They should work the same way in your body. That said, some people report noticing differences when they switch. Individual responses vary, and if you feel a change, that’s worth discussing with your prescriber rather than dismissing.
Can I really get part of my prescription now and the rest later?
Federal law permits it with proper documentation. The pharmacy needs to record the partial fill and complete it within specific timeframes. State regulations add their own requirements on top of federal rules, so the exact details depend on where you live. Your pharmacist can explain what’s allowed in your state.
What Comes Next
The quota increases represent genuine progress. They acknowledge the shortage is real and remove a bureaucratic barrier to increasing supply. But progress doesn’t equal instant resolution.
Manufacturing capacity takes time to scale. Raw materials need to be sourced, often globally. Production runs follow strict timelines and testing protocols. Distribution networks have their own rhythms and constraints. The medication you need might start appearing consistently in three months, or six, or it might show up sporadically for a while before stabilizing.
The October expansion to cover d-amphetamine and methylphenidate should help broaden overall stimulant availability, but different products will normalize on different schedules. Your experience will depend on variables that feel frustratingly random: your specific medication, your dose, your geographic area, your pharmacy’s ordering relationships.
In the meantime, the strategies above give you real options. Electronic prescription transfers, partial fills, dosage adjustments, telehealth access, and conversations about alternative medications can help you stay on treatment while the system catches up. Your pharmacist and prescriber are your best allies in this. They understand the landscape and can help you navigate what’s available right now.
This situation isn’t your fault. You’re managing something genuinely difficult, and the system has made it harder than it should be. The quota increases point in the right direction, but they’re not a magic solution. Stay in touch with your care team, ask about your options, and be patient with yourself while we all wait for supply to stabilize.
You deserve consistent access to the medication that helps you function. Until that becomes reality again, lean on the professionals who can help you find workarounds and stay safe.
Works Cited
DEA. “Adjustment to the Aggregate Production Quota for Lisdexamfetamine and d-Amphetamine (for Conversion) for 2025 Pursuant to 21 U.S.C. 826(h).” Federal Register, September 19, 2025. https://www.federalregister.gov/documents/2025/09/19/2025-18110/adjustment-to-the-aggregate-production-quota-for-lisdexamfetamine-and-d-amphetamine-for-conversion
DEA. “Adjustment to the Aggregate Production Quota for d-Amphetamine (For Sale) and Methylphenidate (For Sale) for 2025 Pursuant to 21 U.S.C. 826(h).” Federal Register, October 2, 2025. https://www.federalregister.gov/documents/2025/10/02/2025-19335/adjustment-to-the-aggregate-production-quota-for-d-amphetamine-for-sale-and-methylphenidate-for-sale
DEA and HHS. “Third Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications.” Federal Register, November 19, 2024. https://www.federalregister.gov/documents/2024/11/19/2024-27018/third-temporary-extension-of-covid-19-telemedicine-flexibilities-for-prescription-of-controlled
American Society of Health-System Pharmacists. “Lisdexamfetamine Capsules.” Drug Shortages Database. https://www.ashp.org/drug-shortages/current-shortages/drug-shortage-detail.aspx?id=961
American Society of Health-System Pharmacists. “Amphetamine Mixed Salts, Immediate-Release Tablets.” Drug Shortages Database. https://www.ashp.org/drug-shortages/current-shortages/drug-shortage-detail.aspx?id=857
DEA. “Transfer of Electronic Prescriptions for Schedules II-V Controlled Substances Between Pharmacies for Initial Filling.” Federal Register, July 27, 2023. https://www.federalregister.gov/documents/2023/07/27/2023-15847/transfer-of-electronic-prescriptions-for-schedules-ii-v-controlled-substances-between-pharmacies-for
U.S. Government Publishing Office. “21 CFR 1306.13 – Partial filling of prescriptions.” Electronic Code of Federal Regulations. https://www.ecfr.gov/current/title-21/chapter-II/part-1306/subject-group-ECFR8588b52940237ef/section-1306.13
U.S. Food and Drug Administration. “Current Good Manufacturing Practice (CGMP) Regulations.” https://www.fda.gov/drugs/pharmaceutical-quality-resources/current-good-manufacturing-practice-cgmp-regulations
DEA Diversion Control Division. “Suspicious Orders (SORS) Q&A.” https://www.deadiversion.usdoj.gov/faq/sors-faq.html
Virginia Health Catalyst. “Strategies for Navigating Stimulant Drug Shortages.” https://www.vhan.com/strategies-for-navigating-stimulant-drug-shortages/
National Institute for Health and Care Excellence. “Attention deficit hyperactivity disorder: diagnosis and management.” 2018. https://www.nice.org.uk/guidance/ng87/chapter/recommendations
Centers for Disease Control and Prevention. “Health Alert Network (HAN) – 00510: Disrupted Access to Prescription Stimulant Medications Could Increase Risk of Injury and Overdose.” June 13, 2024. https://www.cdc.gov/han/2024/han00510.html
U.S. Food and Drug Administration. “Evaluation of Therapeutic Equivalence.” https://www.fda.gov/media/160054/download
U.S. Food and Drug Administration. “Vyvanse (lisdexamfetamine dimesylate) Label.” AccessData FDA. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021977s046%2C208510s003lbl.pdf
Drugs.com. “Lisdexamfetamine Dimesylate Capsule Shortage.” https://www.drugs.com/drug-shortages/lisdexamfetamine-dimesylate-capsule-136